Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of modeling and simulation software for pharmaceutical discovery and development, today announced that it has been accepted into the SimInhale COST (European Cooperation in Science and Technology) Action, a consortium composed of approximately 100 current university, research institute, and industry members from across Europe.

As one of only two U.S. participants, Simulations Plus will participate in activities designed to:

  • advance particle designs for improved deposition and interaction with lung tissue
  • promote realistic computer simulations of particle aerosolization, delivery and deposition
  • promote patient-tailored inhaled medicines
  • promote integration of device and formulation design
  • promote critical assessment of toxicity issues and related risks

SimInhale will establish a roadmap to realistic computer simulations that will provide quantitative data to designers of aerosolized medicines and inhalation devices. Simulations Plus was invited to join SimInhale because of its state-of-the-art Pulmonary Compartmental Absorption and Transit (PCAT™) Module in its industry-leading GastroPlus™ physiologically based pharmacokinetics (PBPK) software program. Simulations Plus scientists will participate in several Working Groups within SimInhale.

John DiBella, vice president for marketing and sales for Simulations Plus, said, “Our acceptance into this prestigious group validates our expertise with aerosolization, and gives us the opportunity to work directly with the outstanding members of SimInhale for the advancement of simulation technology for inhaled medicines. We will participate as full members with access to data and expertise that will help us to improve our pulmonary model to better serve industry, regulatory agencies, and academia in this important area.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more information, visit our website at www.simulations-plus.com.


Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue
651-653-1854
cameron@haydenir.com